Usability Study Completed, Paving Way for FDA 510(k) Submission
INBS sits 19% above its 52-week low of $1.52 on light trading volume (0.3× avg).
Summary
Intelligent Bio Solutions completed a Usability Study showing its fingerprint drug screening system can be used accurately by operators with no specialist background. This is a new milestone in the FDA 510(k) submission program, following precision testing, interference study, and cybersecurity resolution. The company remains on track to submit the 510(k) package in H2 2026, targeting the U.S. drug screening market. With a market cap under $5M and a going concern warning, regulatory progress is critical for survival.
At the time of this announcement, INBS was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $1.52 to $24.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.